SmithKline worldwide OTC sales up 18% to $536 mil. in first quarter.
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE WORLDWIDE OTC SALES UP 18% TO $536 MIL. in the first quarter, led by a 40% gain in the U.S. The increase in U.S. sales was paced by the company's Nicoderm CQ and Nicorette smoking cessation products, which had combined sales of $98 mil., SmithKline Beecham said. Operating profit for the consumer healthcare group rose 20% to $101.1 mil.